T1	Participants 64 126	hospitalized patients with lower respiratory tract infections.
T2	Participants 272 327	121 patients was studied; 92 were clinically evaluable.
T3	Participants 338 410	59 patients were treated with ofloxacin and 33 with the comparator drug.
